Cargando…
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes
Histone deacetylase (HDAC) inhibitors are promising new epi-drugs, but the presence of both class I and class II enzymes in HDAC complexes precludes a detailed elucidation of the individual HDAC functions. By using the class II-specific HDAC inhibitor MC1568, we separated class I- and class II-depen...
Autores principales: | Nebbioso, Angela, Manzo, Fabio, Miceli, Marco, Conte, Mariarosaria, Manente, Lucrezia, Baldi, Alfonso, De Luca, Antonio, Rotili, Dante, Valente, Sergio, Mai, Antonello, Usiello, Alessandro, Gronemeyer, Hinrich, Altucci, Lucia |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693879/ https://www.ncbi.nlm.nih.gov/pubmed/19498465 http://dx.doi.org/10.1038/embor.2009.88 |
Ejemplares similares
-
Targeting HDAC2-Mediated Immune Regulation to Overcome Therapeutic Resistance in Mutant Colorectal Cancer
por: Conte, Mariarosaria, et al.
Publicado: (2023) -
Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2
por: Jayathilaka, Nimanthi, et al.
Publicado: (2012) -
HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape
por: Conte, Mariarosaria, et al.
Publicado: (2014) -
HDAC2‐dependent miRNA signature in acute myeloid leukemia
por: Conte, Mariarosaria, et al.
Publicado: (2019) -
Specific Control of Pancreatic Endocrine β- and δ-Cell Mass by Class IIa Histone Deacetylases HDAC4, HDAC5, and HDAC9
por: Lenoir, Olivia, et al.
Publicado: (2011)